Tolerability and safety of HIV protease inhibitors in adults.
about
Low dose versus high dose stavudine for treating people with HIV infectionClinical use of cobicistat as a pharmacoenhancer of human immunodeficiency virus therapyHIV-associated lipodystrophy: a review from a Brazilian perspectiveHIV Protease Inhibitors: Effect on the Opportunistic Protozoan Parasites.Cigarette smoking in the HIV-infected population.Impact of antiretroviral therapy on lipid metabolism of human immunodeficiency virus-infected patients: Old and new drugs.Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s).Current concepts in the diagnosis and management of metabolic complications of HIV infection and its therapy.Metabolic complications and treatment of perinatally HIV-infected children and adolescents.HIV protease inhibitors: recent clinical trials and recommendations on use.Metabolic Disorders in HIV-Infected Adolescents Receiving Protease Inhibitors.Safety of pharmacoenhancers for HIV therapy.Effect of darunavir on lipid profile in HIV-infected patients.In vitro characterization of GS-8374, a novel phosphonate-containing inhibitor of HIV-1 protease with a favorable resistance profile.Low prevalence of lipodystrophy in HIV-infected Senegalese children on long-term antiretroviral treatment: the ANRS 12279 MAGGSEN Pediatric Cohort Study
P2860
Q24242088-5D10FC3E-F792-4C66-B46C-BC03FC88BC87Q26771182-DFBDDE85-970A-4431-A50D-416D756614A6Q33939681-AEE2C44E-571A-480C-83FF-92306311D2FEQ35012924-6B86BCE6-1B85-4AC2-B0D2-63CD9559E396Q35095054-364D0C16-5402-47E5-95E7-FDC88E04AB89Q35567828-9E08D983-B3D8-4263-8CE5-EC1E6D74393FQ35637346-93B270E8-10B0-43A6-B2CA-F455C7DBC6DFQ36555731-65BD1488-939B-48EF-8989-83CA586AB299Q36952291-E685A0FA-A9A5-45CC-85B1-C80B64D75B4CQ37519715-79298817-0FE8-4406-9CBD-73668C5B4AD7Q37673041-0E0E711B-78E1-46C2-993C-58E3F2271B9CQ38057371-0F92039D-E5C8-41D9-8644-81CAA89391DEQ38058385-8471A22A-A94B-4E0A-8C1D-841B856EC3A8Q41875646-0365C1AF-E07F-4D67-9A2B-40C007C6F000Q58798902-FCCC6A27-41F0-4054-B68A-DB275248D080
P2860
Tolerability and safety of HIV protease inhibitors in adults.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Tolerability and safety of HIV protease inhibitors in adults.
@ast
Tolerability and safety of HIV protease inhibitors in adults.
@en
type
label
Tolerability and safety of HIV protease inhibitors in adults.
@ast
Tolerability and safety of HIV protease inhibitors in adults.
@en
prefLabel
Tolerability and safety of HIV protease inhibitors in adults.
@ast
Tolerability and safety of HIV protease inhibitors in adults.
@en
P1476
Tolerability and safety of HIV protease inhibitors in adults.
@en
P2093
Paul E Sax
Princy Kumar
P304
P356
10.1097/01.QAI.0000138420.38995.86
P407
P577
2004-09-01T00:00:00Z